CHMP RECOMMENDS APPROVAL OF JOHNSON & JOHNSON’S TALVEY®▼ (TALQUETAMAB) PLUS DARATUMUMAB IN EARLIER LINE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

Reuters · 3d ago

Please log in to view news